EGFR-Mutated Lung Cancer With T790M-Acquired Resistance in the Brain and Histologic Transformation in the Lung

被引：31
作者：
Scher, Kevin S. [1 ]
Saldivar, Juan-Sebastian [1 ]
Fishbein, Michael [2 ]
Marchevsky, Alberto [3 ]
Reckamp, Karen L. [1 ]
机构：
[1] City Hope Comprehens Canc Ctr, Duarte, CA USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[3] Cedars Sinai Med Ctr, Hollywood, CA USA
来源：
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2013年 / 11卷 / 09期
关键词：
ERLOTINIB; GEFITINIB;
D O I：
10.6004/jnccn.2013.0126
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
This case report describes the rare occurrence of a T790M resistance mutation found in a central nervous system (CNS) parenchymal metastasis. A concomitant squamous histology transformation in a lung non-T790M-resistant metastasis is also described. The authors hypothesize that this CNS resistance and histology transformation may have resulted from intermittent use of erlotinib treatment. This case report emphasizes the complexities of using erlotinib in the induction setting.
引用
收藏
页码：1040 / 1044
页数：5
相关论文
共 22 条
  • [1] Blay JY, 2007, J CLIN ONCOL, V25, P1107, DOI 10.1200/JCO.2006.09.0183
  • [2] Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling
    Chmielecki, Juliann
    Foo, Jasmine
    Oxnard, Geoffrey R.
    Hutchinson, Katherine
    Ohashi, Kadoaki
    Somwar, Romel
    Wang, Lu
    Amato, Katherine R.
    Arcila, Maria
    Sos, Martin L.
    Socci, Nicholas D.
    Viale, Agnes
    de Stanchina, Elisa
    Ginsberg, Michelle S.
    Thomas, Roman K.
    Kris, Mark G.
    Inoue, Akira
    Ladanyi, Marc
    Miller, Vincent A.
    Michor, Franziska
    Pao, William
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (90)
  • [3] Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
    Gerlinger, Marco
    Rowan, Andrew J.
    Horswell, Stuart
    Larkin, James
    Endesfelder, David
    Gronroos, Eva
    Martinez, Pierre
    Matthews, Nicholas
    Stewart, Aengus
    Tarpey, Patrick
    Varela, Ignacio
    Phillimore, Benjamin
    Begum, Sharmin
    McDonald, Neil Q.
    Butler, Adam
    Jones, David
    Raine, Keiran
    Latimer, Calli
    Santos, Claudio R.
    Nohadani, Mahrokh
    Eklund, Aron C.
    Spencer-Dene, Bradley
    Clark, Graham
    Pickering, Lisa
    Stamp, Gordon
    Gore, Martin
    Szallasi, Zoltan
    Downward, Julian
    Futreal, P. Andrew
    Swanton, Charles
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (10) : 883 - 892
  • [4] A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19
    Goss, G. D.
    Lorimer, I.
    Tsao, M. S.
    O'Callaghan, C. J.
    Ding, K.
    Masters, G. A.
    Roberts, P.
    Jett, J. R.
    Edelman, M. J.
    Shepherd, F. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [5] Rebiopsy of Non-Small Cell Lung Cancer Patients With Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor
    Hata, Akito
    Katakami, Nobuyuki
    Yoshioka, Hiroshige
    Takeshita, Jumpei
    Tanaka, Kosuke
    Nanjo, Shigeki
    Fujita, Shiro
    Kaji, Reiko
    Imai, Yukihiro
    Monden, Kazuya
    Matsumoto, Takeshi
    Nagata, Kazuma
    Otsuka, Kyoko
    Tachikawa, Ryo
    Tomii, Keisuke
    Kunimasa, Kei
    Iwasaku, Masahiro
    Nishiyama, Akihiro
    Ishida, Tadashi
    Nishimura, Yoshihiro
    [J]. CANCER, 2013, 119 (24) : 4325 - 4332
  • [6] Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib
    Jackman, David M.
    Holmes, Alison J.
    Lindeman, Neal
    Wen, Patrick Y.
    Kesari, Santosh
    Borras, Ana M.
    Bailey, Christopher
    de Jong, Francisca
    Jaenne, Pasi A.
    Johnson, Bruce E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (27) : 4517 - 4520
  • [7] Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations
    Janjigian, Yelena Y.
    Park, Bernard J.
    Zakowski, Maureen F.
    Ladanyi, Marc
    Pao, William
    D'Angelo, Sandra P.
    Kris, Mark G.
    Shen, Ronglai
    Zheng, Junting
    Azzoli, Christopher G.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (03) : 569 - 575
  • [8] Neoadjuvant (induction) erlotinib response in stage IIIA non-small-cell lung cancer
    Kappers, Ingrid
    Klomp, Houke M.
    Burgers, Jacobus A.
    Van Zandwijk, Nico
    Haas, Rick L. M.
    van Pel, Renee
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (25) : 4205 - 4207
  • [9] Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: Rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry
    Kawahara, Akihiko
    Azuma, Koichi
    Sumi, Akiko
    Taira, Tomoki
    Nakashima, Kazutaka
    Aikawa, Emiko
    Abe, Hideyuki
    Yamaguchi, Tomohiko
    Takamori, Shinzo
    Akiba, Jun
    Kage, Masayoshi
    [J]. LUNG CANCER, 2011, 74 (01) : 35 - 40
  • [10] Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023
    Kelly, Karen
    Chansky, Kari
    Gaspar, Laurie E.
    Albain, Kathy S.
    Jett, James
    Ung, Yee C.
    Lau, Derick H. M.
    Crowley, John J.
    Gandara, David R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15) : 2450 - 2456
123